Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 651-658, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (31)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robertson, D. M.
Right arrow Articles by McGuckin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robertson, D. M.
Right arrow Articles by McGuckin, M.
Related Collections
Right arrow Laboratory Management
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1999;45:651-658.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Combined Inhibin and CA125 Assays in the Detection of Ovarian Cancer

David M. Robertson1,a, Nicholas Cahir1, Henry G. Burger1, Pamela Mamers2, Philip I. McCloud3, Kim Pettersson4 and Michael McGuckin5

1 Prince Henry's Institute of Medical Research, Clayton, Victoria 3168, Australia.
Departments of
2 Obstetrics and Gynecology and
3 Mathematics, Monash University, Monash Medical Centre, Clayton, Victoria 3168, Australia.

4 Department of Biotechnology, University of Turku, Turku SF-20500, Finland.

5 Department of Obstetrics and Gynecology, University of Queensland, Herston, Queensland 4006, Australia.
a Author for correspondence. Fax 61 3 9550 6125; e-mail david.robertson{at}med.monash.edu.au

Background: The reproductive hormone inhibin has been used as a diagnostic marker of ovarian mucinous and granulosa cell cancers. The aims of this study were to develop a new inhibin immunofluorometric assay ({alpha}C IFMA) to replace an inhibin RIA as a diagnostic marker of these ovarian cancers and to assess whether the {alpha}C IFMA in combination with CA125, which detects serous cancers, leads to an improved biochemical diagnosis of all ovarian cancers.

Methods: Serum inhibin concentrations were determined in healthy postmenopausal women (n = 165) and women with ovarian cancers (n = 154), using an inhibin RIA and an {alpha}C IFMA, which detects inhibin forms containing the {alpha}C subunit as well as the free {alpha}C subunit.

Results: The {alpha}C IFMA gave a similar or better discrimination of mucinous (90% vs 71%) and granulosa cell (100% vs 100%) cancers compared with the inhibin RIA. Combination of CA125 and {alpha}C IFMA values by canonical variate analysis or by multiROC analysis showed that the percentage of all ovarian cancers detected was significantly increased compared with either CA125 or {alpha}C IFMA alone.

Conclusions: The {alpha}C IFMA shows a similar or better specificity compared with the RIA, but with increased sensitivity. In combination with CA125, the {alpha}C IFMA provides an effective dual test for the detection of the majority (90%) of ovarian cancers.© 1999 American Association for Clinical Chemistry




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Tsigkou, D. Marrelli, F. M. Reis, S. Luisi, A. L. Silva-Filho, F. Roviello, S. A. Triginelli, and F. Petraglia
Total Inhibin Is a Potential Serum Marker for Epithelial Ovarian Cancer
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2526 - 2531.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
A. L. Marca and A. Volpe
The Anti-Mullerian hormone and ovarian cancer
Hum. Reprod. Update, May 1, 2007; 13(3): 265 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
G. E. Owens, R. A. Keri, and J. H. Nilson
Ovulatory Surges of Human CG Prevent Hormone-Induced Granulosa Cell Tumor Formation Leading to the Identification of Tumor-Associated Changes in the Transcriptome
Mol. Endocrinol., June 1, 2002; 16(6): 1230 - 1242.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. M. Robertson, T. Stephenson, E. Pruysers, P. McCloud, A. Tsigos, N. Groome, P. Mamers, and H. G. Burger
Characterization of Inhibin Forms and Their Measurement by an Inhibin {alpha}-Subunit ELISA in Serum from Postmenopausal Women with Ovarian Cancer
J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 816 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
G. P. Risbridger, J. F. Schmitt, and D. M. Robertson
Activins and Inhibins in Endocrine and Other Tumors
Endocr. Rev., December 1, 2001; 22(6): 836 - 858.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.